Docoh
Loading...

AMEH Apollo Medical

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


Apollo Medical Holdings, Inc. (“ApolloMed”) held its 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”) on June 17, 2021. At the close of business on April 28, 2021, the record date for the 2021 Annual Meeting (the “Record Date”), there were 54,996,738 shares of common stock, par value $0.001 per share, of ApolloMed, issued and outstanding, each share being entitled to one vote and to be voted together as one class vote at the 2021 Annual Meeting. At the 2021 Annual Meeting, there were present in person or by proxy 40,439,251 shares of ApolloMed’s common stock, representing stockholders entitled to cast approximately 73.53% of the total outstanding eligible votes and constituting a quorum. As of the Record Date, 1,111,111 shares of ApolloMed’s Series A preferred stock and 555,555 shares of ApolloMed’s Series B preferred stock, par value $0.001 per share, were held by Network Medical Management, Inc., a wholly-owned subsidiary of ApolloMed, and therefore, pursuant to the Delaware General Corporation Law, such shares of preferred stock were not voted, nor counted for quorum purposes, at the 2021 Annual Meeting.




Set forth below are the voting results for the three proposals considered and voted upon at the 2021 Annual Meeting, all of which were described in ApolloMed’s definitive proxy statement for the 2021 Annual Meeting, filed with the Securities and Exchange Commission on April 29, 2021:




Proposal 1. Election of Directors




ApolloMed’s stockholders elected, by the votes indicated below, eleven persons to serve as directors of ApolloMed until its 2022 Annual Meeting of Stockholders and until their successors are duly elected and qualify. The following sets forth the results of the voting with respect to each candidate:




DirectorForWithheldBroker Non-Votes (1)
Kenneth Sim, M.D.35,332,152204,028 4,903,071
Thomas S. Lam, M.D., M.P.H.35,341,388194,792 4,903,071
Mitchell W. Kitayama31,704,4463,831,734 4,903,071
David G. Schmidt33,212,7202,323,460 4,903,071
Mark Fawcett33,730,1201,806,060 4,903,071
Michael F. Eng35,267,667268,513 4,903,071
Li Yu35,267,387268,793 4,903,071
Ernest A. Bates, M.D.33,400,7432,135,437 4,903,071
Linda Marsh35,210,109326,071 4,903,071
John Chiang33,679,9871,856,193 4,903,071
Matthew Mazdyasni35,017,037519,143 4,903,071


(1) Broker non-votes represent proxies that are uninstructed on a proposal and submitted by brokers or other nominees who lack discretionary authority to vote on the proposal absent instructions from the beneficial owner of shares of stock.




Based on these voting results, each of the eleven nominees for director were elected to serve until ApolloMed’s 2022 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified.







Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm




ApolloMed’s stockholders voted to ratify the appointment of Ernst & Young LLP as ApolloMed’s independent registered public accounting firm for the fiscal year ending December 31, 2021. 40,291,476 votes were cast “for” the ratification, 147,187 votes were cast “against” the ratification and 588 votes abstained. There were no broker non-votes for this proposal.




Based on these voting results, the stockholders ratified the appointment of Ernst & Young LLP as ApolloMed’s independent registered public accounting firm for the fiscal year ending December 31, 2021.
















Proposal 3. Approval of the Amendment of the Company's 2015 Equity Incentive Plan




ApolloMed’s stockholders voted to approve the amendment of the Company's 2015 Equity Incentive Plan to increase the maximum number of shares authorized for issuance thereunder by 2,000,000 shares, from 1,500,000 shares to 3,500,000 shares. 27,368,444 votes were cast “for” the approval, 7,816,984 votes were cast “against” the approval, 350,752 votes abstained and 4,903,071 broker non-votes for this proposal.




Based on these voting results, the stockholders approved the amendment of the Company's 2015 Equity Incentive Plan to increase the maximum number of shares authorized for issuance thereunder by 2,000,000 shares, from 1,500,000 shares to 3,500,000 shares.